发布求助
文献互助 智能选刊 最新文献

International journal of pharmaceutical compounding最新文献

筛选
英文 中文
PreScription: Changes Are Coming! 处方：变革即将来临
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Loyd V Allen
{"title":"PreScription: Changes Are Coming!","authors":"Loyd V Allen","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"444"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Drug Utilization Review: Our Patients Deserve Our Very Best. 药物使用审查：我们的患者值得我们做到最好。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Kathleen Jackson
{"title":"Drug Utilization Review: Our Patients Deserve Our Very Best.","authors":"Kathleen Jackson","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In 1990, the Omnibus Budget Reconciliation Act included requirements for Medicaid patients in an effort to save the federal government money. The requirements included a prospective drug utilization review, patient counseling, and maintenance of patient records. Subsequently, in 1993, when the pharmacy practice requirements went into effect, this federal regulation became the standard of care for pharmacists and part of their professional duty. This article suggests that the pharmacy should review all active pharmaceutical ingredients and excipients that are dispensed at the pharmacy and list all interactions or potential side effects in the review, so that a proper drug utilization review can be performed.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"450-453"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlighting the Benefits of AlpaWash in Wound Care: Case Reports in Small Animals. 突出 AlpaWash 在伤口护理中的优势：小动物病例报告。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Flávia Semighini, Laís de Azevedo Fornaciari, Vanessa Pinheiro, Rodrigo Lupatini, Halema Haiub, Erica Cull, Raman Sidhu
{"title":"Highlighting the Benefits of AlpaWash in Wound Care: Case Reports in Small Animals.","authors":"Flávia Semighini, Laís de Azevedo Fornaciari, Vanessa Pinheiro, Rodrigo Lupatini, Halema Haiub, Erica Cull, Raman Sidhu","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Several studies have reported the potential of utilizing natural extracts in wound care, emphasizing those with anti-inflammatory and antimicrobial properties. In veterinary medicine, dermal-lesion treatment can be very challenging considering the patient's compliance and awareness of their condition. In this article, six veterinary case reports have been presented to elucidate the advantages of AlpaWash, a topical application utilized in combination with the prescribed medications of the patients, for the purpose of addressing the process of wound healing in three cats and three dogs. All animals were admitted to the veterinary clinic and treated under the supervision of a veterinarian. The cats and dogs were rescued from streets by people who lived in the neighborhood of Cão Bento´s Veterinary. They were admitted for the purpose of receiving medical care due to recent minor injuries or wounds due to a pet fight, preexisting condition, or accident. A veterinarian performed the anamnesis and monitored the animals during the period of treatment with AlpaWash. In each case report, the veterinarian observed significant improvement in the wound closures, and lesions healed within a couple of weeks to a couple of months depending on the case. The outcomes demonstrate the benefits of AlpaWash topical application and suggest that AlpaWash may be an alternative vehicle for compounded preparations in wound management.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"454-460"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803706","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients. 非无菌配制基础知识：使用美国食品和药物管理局批准的商业产品作为配料。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Loyd V Allen
{"title":"Nonsterile Basics of Compounding: Using U.S. Food and Drug Administration-approved Commercial Products as Ingredients.","authors":"Loyd V Allen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Throughout history, pharmacists have used natural products, chemicals, and other materials for prescription compounding. In the past, these chemicals and materials were obtained from natural preparations, raw materials, and even household ingredients. Today, compounding pharmacists use chemicals from various legitimate sources, depending on availability and may even use manufactured drug products as the drug source for compounding (this is especially true in hospital intravenous admixture programs).</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"474-481"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management. 案例研究：个性化口服小剂量纳曲酮用于疼痛治疗。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Franklin Rodriguez, Maria Carvalho, Fabiana Banov
{"title":"Case Study: Personalized Oral Low-dose Naltrexone Titration for Pain Management.","authors":"Franklin Rodriguez, Maria Carvalho, Fabiana Banov","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Naltrexone is a competitive opioid receptor antagonist indicated to treat opioid and alcohol dependence. In the U.S., naltrexone is commercially available as 50-mg tablets, and the adult dosage strength typically ranges between 50 mg once daily and 100 mg once daily. However, there is evidence to suggest that naltrexone prescribed in low doses, about 1/10th of the daily standard dosage, may be effective in managing a myriad of chronic conditions, including pain refractory to conventional pharmacological treatments. The U.S. Food and Drug Administration recently granted an orphan drug designation for low-dose naltrexone for the treatment of complex regional pain syndrome. This article provides a case study of a patient who was treated with a low dose of naltrexone for pain associated with the diagnosis of idiopathic hypereosinophilic syndrome.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"468-473"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sterile Basics of Compounding: Allowable Endotoxin Levels in Parenteral Preparations. 复方制剂的无菌基础知识：肠外制剂中允许的内毒素含量。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Loyd V Allen
{"title":"Sterile Basics of Compounding: Allowable Endotoxin Levels in Parenteral Preparations.","authors":"Loyd V Allen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inadvertent administration of endotoxins to humans may result in a number of events, ranging from fever, through a cascade of pathogenic responses, to death. Endotoxins are potent, toxic, and very stable and are present in many pharmaceutical ingredients and on surfaces that come into contact with preparations formulated for parenteral administration. Endotoxins are very difficult to eliminate in a final preparation, therefore, procedures are generally directed at eliminating endotoxins during the preparation process. This article discusses the allowable endotoxin levels in parenteral preparations.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"483-486"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Considerations in Qualifying Critical Suppliers. 对关键供应商进行资格审查的考虑因素。
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Amy Summers
{"title":"Considerations in Qualifying Critical Suppliers.","authors":"Amy Summers","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The impending updates to United States Pharmacopeia Chapter <797> and Chapter <795> specify that compounders must obtain active pharmaceutical ingredients and should obtain excipients from FDA-registered facilities. Additionally, the U.S. Food and Drug Administration cautions compounders to know their bulk active pharmaceutical ingredients and excipients suppliers. While the U.S. Food and Drug Administration expects 503B outsourcing facilities to qualify their critical suppliers, pharmacy boards and accrediting bodies are beginning to ask 503A compounders for their list of approved suppliers and how they qualify them. As such, pharmacies should become comfortable in qualifying suppliers as part of their quality assurance program. This article discusses how pharmacies can apply the elements of supplier qualification to their practice to ensure that critical supplies and services meet company specifications for quality and compliance.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"461-466"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Compounded "Monster Spray" for Nighttime Terrors: A Case Report. 治疗夜间恐惧症的复方 "怪物喷雾剂"：病例报告
International journal of pharmaceutical compounding Pub Date : 2023-11-01
Mike Riepl
{"title":"Compounded \"Monster Spray\" for Nighttime Terrors: A Case Report.","authors":"Mike Riepl","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Among the challenges most difficult to treat in the spectrum of pediatric anxieties are severe, persistent nighttime terrors (e.g., anticipating or \"perceiving\" the presence of monsters or other creatures under the bed or in the closet, nightmares) that disrupt a child's sleep, impact his or her overall adjustment, negatively affect the quality of family life, and may eventually require clinical assessment and intervention. This article describes a compounded preparation that has proven successful in combatting such fears and enabling the recovery of children so afflicted.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 6","pages":"446-448"},"PeriodicalIF":0.0,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138803682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Basics of Sterile Compounding: Sterile Basics of Compounding Intravenous Admixtures, Part 4: Physicochemical Considerations. 无菌配制基础：配制静脉外加剂的无菌基础，第4部分：理化因素。
International journal of pharmaceutical compounding Pub Date : 2023-09-01
Loyd V Allen
{"title":"Basics of Sterile Compounding: Sterile Basics of Compounding Intravenous Admixtures, Part 4: Physicochemical Considerations.","authors":"Loyd V Allen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Intravenous admixture compounding is common practice in most hospitals throughout the world, regardless of the country. Compounding intravenous medications involves risk, as there is a high potential for error due to their complexity in compounding as well as the additional issues that working in an aseptic compounding environment poses for the compounder. This article in a series of intravenous admixture compounding discusses considerations involved when using commercial products in compounding, as well as a discussion on the issues of freezing, solubility, sorption, leaching, incompatibilities, and quality control, with an emphasis on physicochemical considerations.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 5","pages":"397-409"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41201149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Excipients and Adverse Events. 辅料和不良事件。
International journal of pharmaceutical compounding Pub Date : 2023-09-01
Loyd V Allen
{"title":"Excipients and Adverse Events.","authors":"Loyd V Allen","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Pharmaceutical excipients are substances formulated with an active ingredient in a medication. This article has provided a brief discussion on excipients, the purpose of excipients, the selection of appropriate excipients, the use of excipients in formulation development by compounding pharmacists/manufacturers, excipient examples and usage, the numerous incompatibilities that should be considered when choosing an excipient, and a list of adverse effects related to excipients.</p>","PeriodicalId":14381,"journal":{"name":"International journal of pharmaceutical compounding","volume":"27 5","pages":"382-385"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41201153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信